Early psychosis biomarker profiles and care outcomes
2/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
This project uses brain, eye movement, and thinking tests to group young people with early psychosis so doctors can better predict how they will do in specialty care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11139537 on NIH RePORTER |
What this research studies
If I join, researchers will collect EEG, eye-movement, and neurocognitive tests along with clinical and demographic information to sort participants into three biological 'Biotypes.' They will follow about 320 people with early course psychosis across five coordinated specialty care clinics and check progress at 1, 6, and 12 months. The team will compare these Biotypes and clinical data to find patterns linked to recovery, treatment resistance, or functional decline. Those patterns would be used to help tailor the type, timing, and intensity of care early in illness.
Who could benefit from this research
Good fit: Ideal candidates are people roughly 18–35 years old in the early course of psychosis (including bipolar disorder with psychosis, schizophrenia, or schizoaffective disorder) who are receiving care at participating coordinated specialty care clinics.
Not a fit: People without recent-onset psychosis, those outside the target age range, or those unable to attend the participating clinics are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could help personalize early psychosis care by identifying biological subgroups tied to better or worse recovery.
How similar studies have performed: Previous BSNIP work validated EEG, eye-movement, and cognitive Biotypes in adults with psychosis, while applying these Biotypes to early psychosis is a newer step.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Gershon, Elliot S — University of Chicago
- Study coordinator: Gershon, Elliot S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.